Ionis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.02.19	Novartis To Exercise Its Option To License Rights To Develop TQJ230 (RTTNews)
31.12.18	10 RNA Therapeutics Companies To Watch In 2019 (RTTNews)
25.09.18	AMRN Heartens Investors, AKCA On Watch, ACRX Faces FDA Panel In Oct. (RTTNews)
29.08.18	AKCA Slips On FDA Snub, COCP To Report HCV Data In Q4, VCNX Down 23% This Month (RTTNews)
28.08.18	Ionis Pharmaceuticals, Akcea Therapeutics Sharply Lower In Late-Day Trading (RTTNews)
25.08.18	Week Ahead In Pharmaceuticals: 5 Stocks To Watch (ESPR, TTPH, AQST...) (RTTNews)
26.07.18	Biotech Stocks Facing FDA Decision In August (RTTNews)
12.07.18	AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 (RTTNews)
18.06.18	Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer (PR Newswire)
05.06.18	Ionis Teams With Biogen To Develop Drugs For Neurological Diseases (RTTNews)
05.06.18	Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases (PR Newswire)
23.05.18	Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders (PR Newswire)
21.05.18	Symposium: A Revolutionary New Online Platform Redefining the Meaning of Social Commerce (PR Newswire)
08.05.18	Nelnet Reports First Quarter 2018 Results (PR Newswire)
04.05.18	Ionis Reports First Quarter 2018 Financial Results (PR Newswire)
24.04.18	New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease (PR Newswire)
24.04.18	Ionis Pharmaceuticals to Hold First Quarter 2018 Financial Results Webcast (PR Newswire)
23.04.18	BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD (RTTNews)
20.04.18	Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies (RTTNews)
17.04.18	Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases (PR Newswire)
12.04.18	GoDaddy Inc. Announces First Quarter 2018 Earnings Conference Call (PR Newswire)
09.04.18	Ionis Earns $30 Mln License Fee From AstraZeneca On New Drug Advancement (RTTNews)
09.04.18	Ionis and AstraZeneca Advance New Drug for NASH (PR Newswire)
26.03.18	Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis (PR Newswire)
23.03.18	Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders (PR Newswire)
15.03.18	Ionis and Akcea Partner to Commercialize Inotersen for hATTR (PR Newswire)
06.03.18	Ionis Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
05.03.18	Complete College America Sets Sights on Comprehensive Software Solutions with Third Annual Technology Seal of Approval (PR Newswire)
01.03.18	IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease (PR Newswire)
27.02.18	Ionis Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
20.02.18	Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca (PR Newswire)
13.02.18	Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call (PR Newswire)
31.01.18	Qualcomm and Samsung Announce Expanded Strategic Relationship (PR Newswire)
11.01.18	Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer (PR Newswire)
08.01.18	Ionis' Inotersen NDA Accepted for Priority Review by the FDA (PR Newswire)
21.12.17	Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal Disorders (PR Newswire)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
18.12.17	Ionis' License Agreement for Huntington's Disease Drug, IONIS-HTT Rx, Receives HSR Clearance (PR Newswire)
11.12.17	Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease (PR Newswire)
07.12.17	Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (PR Newswire)
16.11.17	Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen (PR Newswire)
09.11.17	Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure (PR Newswire)
08.11.17	Ionis Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
07.11.17	Ionis Announces Management Transitions (PR Newswire)
07.11.17	Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017 (PR Newswire)
07.11.17	FDA Lifts Hold On CLLS' Trials, Double Delight For Roche, COLL Will Have To Wait (RTTNews)
06.11.17	Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA (PR Newswire)
03.11.17	Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency (PR Newswire)
02.11.17	Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

25.11.24		Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
10.09.24		Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain
10.09.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen
10.09.24		Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell
10.09.24		Freundlicher Handel: NASDAQ Composite startet im Plus
30.08.24		Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus
27.08.24		Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

25.11.24

Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

10.09.24

Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain

10.09.24

Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen

10.09.24

Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell

10.09.24

Freundlicher Handel: NASDAQ Composite startet im Plus

30.08.24

Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus

27.08.24

Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ionis Pharmaceuticals Inc

Aktien Top/Flop

Ionis Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten